Innate Immunotherapeutics likely to shutter, CEO says

Rep. Chris Collins, R-N.Y., is the largest shareholder of Innate Immunotherapeutics.

T

he little Australian biotech firm that once counted U.S. Health and Human Services Secretary Tom Price as a shareholder — a link that roiled his Senate confirmation hearing last winter — is facing closure, the company has told shareholders.

Innate Immunotherapeutics will probably shut down in the coming months, CEO Simon Wilkinson said at the company’s annual meeting Wednesday, The Australian, a news outlet, reported.

 

Source; https://www.statnews.com/2017/09/01/innate-immunotherapeutics-closure/

Leave a Reply